Novo Nordisk A/S $NVO Stock Position Lifted by Capital International Inc. CA

Capital International Inc. CA grew its position in Novo Nordisk A/S (NYSE:NVO) by 191.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 233,578 shares of the company’s stock after acquiring an additional 153,428 shares during the quarter. Capital International Inc. CA’s holdings in Novo Nordisk A/S were worth $12,961,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its holdings in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the third quarter worth about $30,000. Allianz SE lifted its holdings in Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after acquiring an additional 238 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S in the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NVO shares. Citigroup began coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. CICC Research assumed coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday. Finally, Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $49.93.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $38.73 on Wednesday. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $82.57. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The stock has a market cap of $172.92 billion, a PE ratio of 11.16 and a beta of 0.73. The company’s 50-day moving average price is $50.93 and its two-hundred day moving average price is $52.11.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Capacity and production investment — Novo is expanding manufacturing in Ireland with ~ $506m to raise oral GLP‑1 output to meet global demand, which supports longer‑term volume growth and supply resilience. Novo expands manufacturing (InsiderMonkey)
• Positive Sentiment: Distribution partnership — Novo agreed to supply Wegovy/Ozempic through Hims & Hers’ telehealth platform, ending a legal dispute and opening a digital channel that could broaden U.S. access and sales. That deal helped calm one litigation front and may support volume. Novo-Hims deal (Reuters)
• Positive Sentiment: Share repurchase — Novo confirmed ongoing share buybacks (part of up to DKK15bn programme), which is supportive for shareholder returns and EPS. Share repurchase programme (GlobeNewswire)
• Neutral Sentiment: Past earnings vs. guidance — Novo beat Q4 consensus on revenue and EPS but earlier issued weak FY2026 guidance that pressured the stock; investors now weigh strong recent results against management’s cautious full‑year outlook. Q4 results & guidance (Seeking Alpha)
• Negative Sentiment: FDA warning letter — The U.S. FDA issued a warning letter after an inspection tied to Plainsboro (early 2025) citing failures in post‑marketing safety reporting for semaglutide products; the regulator flagged potential unreported adverse events including two deaths and a suicide — a material safety/regulatory risk that spooked investors. FDA warning (Reuters) Potential unreported side effects (Forbes)
• Negative Sentiment: Legal / investor risk — A law firm (Pomerantz) has launched an investigation on behalf of investors, increasing potential litigation/legal-cost overhangs. Investor investigation (GlobeNewswire)
• Negative Sentiment: Analyst downgrades and pipeline concerns — TD Cowen cut NVO to Hold and other analysts flagged the pipeline as “not poised to blunt semaglutide loss‑of‑exclusivity” and rising competitive pressure from new GLP‑1 entrants, pressuring forward expectations and valuation. Pipeline downgrade (Yahoo Finance)
• Negative Sentiment: Market reaction / sector weakness — Healthcare indices were weaker intraday as investors rotated away from GLP‑1 names amid safety/regulatory headlines and heightened competition; that broad sentiment hit NVO alongside the specific company news. Sector decline (Yahoo Finance)

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.